Greatmark Investment Partners Inc. cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 30,407 shares of the biopharmaceutical company's stock after selling 2,535 shares during the quarter. Greatmark Investment Partners Inc.'s holdings in Gilead Sciences were worth $3,371,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Price T Rowe Associates Inc. MD increased its position in Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock valued at $1,647,484,000 after buying an additional 11,156,382 shares in the last quarter. Nuveen LLC bought a new position in shares of Gilead Sciences during the first quarter valued at $620,415,000. Kingstone Capital Partners Texas LLC purchased a new position in shares of Gilead Sciences in the 2nd quarter worth about $238,083,000. Los Angeles Capital Management LLC increased its stake in Gilead Sciences by 422.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company's stock valued at $282,706,000 after purchasing an additional 2,040,261 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock worth $13,162,606,000 after buying an additional 1,942,433 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.
Insider Buying and Selling at Gilead Sciences
In other news, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $354,240.00. Following the transaction, the insider directly owned 110,193 shares in the company, valued at $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the transaction, the chief executive officer directly owned 591,203 shares of the company's stock, valued at approximately $66,013,726.98. This trade represents a 1.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,500 shares of company stock valued at $8,281,540 over the last ninety days. 0.27% of the stock is currently owned by company insiders.
Gilead Sciences Stock Performance
Shares of NASDAQ GILD opened at $124.08 on Wednesday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 12-month low of $85.60 and a 12-month high of $124.61. The firm has a market capitalization of $153.96 billion, a price-to-earnings ratio of 24.72, a price-to-earnings-growth ratio of 0.84 and a beta of 0.34. The firm has a 50 day moving average of $115.35 and a 200 day moving average of $110.71.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm's revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date was Monday, September 15th. Gilead Sciences's dividend payout ratio is presently 62.95%.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the stock. The Goldman Sachs Group raised their price target on shares of Gilead Sciences from $105.00 to $108.00 and gave the company a "neutral" rating in a research report on Friday, October 17th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price for the company in a report on Friday, July 25th. Weiss Ratings restated a "buy (b)" rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Finally, Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $108.00 to $127.00 in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $121.14.
Read Our Latest Analysis on Gilead Sciences
Gilead Sciences Company Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
